GLP-1 and SGLT2 Inhibitors: Can You Combine Them for Weight Loss & Liver Health?

Quick answer: Can you combine GLP-1 and SGLT2 inhibitors?

Yes. GLP-1 receptor agonists (semaglutide, tirzepatide) can be safely combined with SGLT2 inhibitors (empagliflozin/Jardiance, dapagliflozin/Farxiga, canagliflozin/Invokana) under medical supervision. The American Diabetes Association (ADA) specifically recommends this combination for patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD). The combo provides synergistic effects: GLP-1s drive significant weight loss and appetite suppression, while SGLT2 inhibitors add blood sugar control, cardiovascular protection, kidney protection, and modest additional weight loss.

What are SGLT2 inhibitors?

SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) are a class of medications that lower blood sugar by blocking glucose reabsorption in the kidneys, causing excess glucose to be excreted through urine. They are FDA-approved for:

• Type 2 diabetes (blood sugar control)
• Heart failure (reduced hospitalization risk)
• Chronic kidney disease (slowed progression)
• Cardiovascular risk reduction

Common SGLT2 inhibitors:

• Empagliflozin (Jardiance) — Also approved for heart failure and CKD
• Dapagliflozin (Farxiga) — Also approved for heart failure and CKD
• Canagliflozin (Invokana) — Also approved for diabetic kidney disease
• Ertugliflozin (Steglatro) — Approved for type 2 diabetes

How the GLP-1 + SGLT2 combination works

GLP-1s and SGLT2 inhibitors work through completely different mechanisms, which is why they complement each other:

ADA recommendation for MASLD/MASH

The American Diabetes Association's 2026 Standards of Care recommend combining GLP-1 receptor agonists with SGLT2 inhibitors for patients with type 2 diabetes and MASLD (metabolic dysfunction-associated steatotic liver disease). The rationale:

• GLP-1s address the root cause (obesity and insulin resistance) through significant weight loss
• SGLT2 inhibitors provide additional metabolic benefits and may reduce hepatic glucose production
• Both classes have cardiovascular and kidney benefits, which are important for MASLD patients who often have multi-organ metabolic disease
• The combination addresses multiple metabolic pathways simultaneously

See our semaglutide for MASH guideand GLP-1 and fatty liver guide.

Weight loss synergy

While SGLT2 inhibitors alone produce modest weight loss (2 to 3 kg), they can enhance the weight loss achieved with GLP-1 medications:

• GLP-1 alone — 15% (semaglutide) to 22.5% (tirzepatide) weight loss
• SGLT2 alone — 2 to 3 kg (4 to 7 lbs) weight loss
• GLP-1 + SGLT2 — Potentially 1 to 2% additional weight loss beyond GLP-1 alone

The additional weight loss from SGLT2 is modest but meaningful, especially for patients who have plateaued on GLP-1 therapy alone.

Safety and side effects

The combination is generally safe, but patients should be aware of potential additive effects:

• Dehydration — Both GLP-1s (via reduced intake) and SGLT2s (via increased urination) can cause dehydration. Drink plenty of fluids. See our dehydration guide.
• Hypoglycemia — Rare with either medication alone, but risk increases if combined with insulin or sulfonylureas. Monitor blood sugar closely.
• Genital yeast infections — SGLT2 side effect due to glucose in urine. More common in women.
• UTI risk — SGLT2s slightly increase urinary tract infection risk.
• Diabetic ketoacidosis (DKA) — Rare but serious SGLT2 risk. Seek immediate medical attention for nausea, vomiting, abdominal pain, or fruity breath odor.
• GI side effects — GLP-1 side effects (nausea, diarrhea, constipation) are additive. See our side effects guide.

Who should consider the GLP-1 + SGLT2 combination?

• Patients with type 2 diabetes who need better blood sugar control
• Patients with MASLD/MASH who need liver fat reduction
• Patients with cardiovascular disease who need multi-organ protection
• Patients with chronic kidney disease who need renal protection
• Patients who have plateaued on GLP-1 therapy alone and want additional metabolic benefits
• Patients with heart failure who need comprehensive metabolic management

Can you also take metformin?

Yes. Many patients with type 2 diabetes take all three medications:

• Metformin — Improves insulin sensitivity, reduces hepatic glucose production
• GLP-1 — Appetite suppression, weight loss, blood sugar control
• SGLT2 — Glucose excretion, heart and kidney protection

See our GLP-1 and metformin guide.

How to get the GLP-1 + SGLT2 combination

1. Talk to your provider — Discuss whether adding an SGLT2 inhibitor to your GLP-1 regimen is appropriate
2. Review your medications — Your provider will check for interactions and adjust doses
3. Monitor blood sugar — Check glucose levels more frequently when starting the combination
4. Stay hydrated — Both medications can cause fluid loss; drink plenty of water
5. Follow up regularly — Schedule check-ins to monitor kidney function, blood sugar, and side effects

FAQ

Related articles

• GLP-1 and Metformin Together
• Semaglutide for MASH
• GLP-1 and Fatty Liver
• GLP-1 for Metabolic Syndrome
• GLP-1 and Heart Health
• GLP-1 and Kidney Health
• GLP-1 Dehydration Guide